Skip to main navigation Skip to search Skip to main content

Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies

  • Joshua I. Barzilay
  • , Peggy Gao
  • , Martin O'Donnell
  • , Johannes F.E. Mann
  • , Craig Anderson
  • , Robert Fagard
  • , Jeffrey Probstfield
  • , Gilles R. Dagenais
  • , Koon Teo
  • , Salim Yusuf
  • Emory University School of Medicine
  • Population Health Research Institute, Ontario
  • Ludwig-Maximilians-University Munich
  • George Institute of International Health
  • KU Leuven University
  • University of Washington School of Medicine
  • Institut Universitaire de Cardiologie et de Pneumologie de Québec

Research output: Contribution to a Journal (Peer & Non Peer)Articlepeer-review

92 Citations (Scopus)

Abstract

Background: Microvascular disease of the kidney (manifesting as albuminuria) and of the brain (manifesting as cognitive decline) may share a common pathogenesis. Gaining an understanding of the concomitant history of these 2 conditions may inform clinical practice and lead to novel prevention and treatment approaches. Methods: A total of 28 384 participants with vascular disease or diabetes mellitus were examined. At baseline and year 5, participants underwent a Mini-Mental State Examination (MMSE) and urine testing for albumin excretion. Multivariable logistic regression was used to determine the association between albumin excretion and MMSE score, cross-sectionally and prospectively, and whether angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker use modified the association. Results: Compared with participants with normoalbuminuria, those with microalbuminuria (odds ratio [OR], 1.26; 95% confidence interval [CI], 1.11-1.44]) and macroalbuminuria (1.49; 1.20-1.85) were more likely to have a reduced MMSE score (<24). On follow-up, participants with baseline albuminuria had increased odds of cognitive decline (decrease in MMSE score ≥3 points) compared with those with normoalbuminuria (microalbuminuria: OR, 1.22; 95% CI, 1.07-1.38; macroalbuminuria: 1.21; 0.94-1.55). Participants who developed new albuminuria had increased odds of cognitive decline during follow-up compared with those who remained normoalbuminuric (new microalbuminuria: OR, 1.30; 95% CI, 1.12-1.52; new macroalbuminuria: 1.77; 1.24-2.54). Participants with baseline macroalbuminuria treated with an angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker had lower odds of MMSE decline than participants treated with placebo. Conclusion: Factors that contribute to albuminuria may contribute to cognitive decline, supporting the notion that both conditions share a common microvascular pathogenesis. Trial Registration: clinicaltrials.gov Identifier: NCT00153101.

Original languageEnglish
Pages (from-to)142-150
Number of pages9
JournalArchives of Internal Medicine
Volume171
Issue number2
DOIs
Publication statusPublished - 24 Jan 2011
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies'. Together they form a unique fingerprint.

Cite this